Amphastar Pharmaceuticals, Inc. reported it Primatene Mist emergency asthma inhaler was a key driver for sales growth of 26% to $120.9m in the fourth quarter and 25% to $437.8m for 2021.
Primatene Mist Drives Amphastar Sales Growth
Amphastar reported double-digit growth in the fourth quarter driven by sales of Primatene Mist, epinephrine products and glucagon. The company also revealed that it is anticipating a Q3 FY22 launch of vasopressin.